Global Liposarcoma Clinical Trials Research Trends- Analysis of Trial Phases, Markets, Recruitment, Trial Types, Enrolment, Intervention and Companies

Global Liposarcoma Clinical Trials Research Trends- Analysis of Trial Phases, Markets, Recruitment, Trial Types, Enrolment, Intervention and Companies

  • August 2017 •
  • 66 pages •
  • Report ID: 5139473
Olaratumab gives hope for Sarcoma Cancer Patients

Liposarcoma clinical trials report from VPA Research provides comprehensive analysis and trends in global Liposarcoma disease clinical trials. The research work analyzes the evolution of Liposarcoma clinical trial trends across countries and regions.

The report focuses on drugs and therapies being evaluated for Liposarcoma treatment in active clinical development phases including phase 1, phase 2, phase 3 and phase 4 clinical trials. The report also provides trials information by region, key countries, phases, trial status and sponsor types.

Our experienced database team dynamically updates the clinical trials data from several sources including Clinical trial registries, conferences, journals and company releases etc. Further, data is presented in user friendly manner to enable readers quick access to Liposarcoma clinical trials.

Scope of the Report-
- Number of Liposarcoma clinical trials across regions- Asia and Oceania, Europe, Middle East Africa and Americas
- Trial information by Phase and Subjects recruited
- Trial information by status, type, sponsor type
- Drugs used for treatment of Liposarcoma
- Both observational and interventional trials analyzed
- Success rates of trials are analyzed
- Trends in enrollment over the past ten years identified
- Leading sponsors of Liposarcoma clinical trials worldwide are listed

Reasons to Buy
- Track competition and design competitive advantages
- Identify right partners to associate with for further research
- Evaluate potential opportunities available in further clinical trials of the disease
- Formulate business development strategies through success rates of clinical trials
- Identify quick markets for recruiting subjects based on trials count by each market

Executive Summary

Liposarcoma is one of the most common sub-types of soft tissue sarcoma. The sub-types vary from a local tumor to highly malignant one.

- Atypical lipomatous tumor (ALT) and well-differentiated liposarcoma (WDLS)- represents a locally aggressive tumor
- Myxoid round cell liposarcoma (MRCL) - These tumors may have a hypercellular round cell component that signifies worse prognosis.
- Pleomorphic liposarcoma- is high-grade subtype, with 34–45% risk of local recurrence and 32–57% risk of metastatic disease.

Some of the Major Developments in the recent past include-
- FDA approves Eribulin Mesylate to show survival benefit in liposarcoma
- Selinexor (KPT-330) for Dedifferentiated Liposarcoma
- Approval of olaratumab Offers hope for Sarcoma Cancer Patients
- Both existing and emerging immunotherapy treatments Likely to be successful for sarcomas

We are very sorry, but an error occurred.
Please contact if the problem remains.

Country=UnitedStates Industry=Cancer ParentIndustry=LifeSciences Date=201708 Topic=ProductInitiative Publisher=VPAResearch Price=2000